REG - Tissue Regenix Group - Result of General Meeting and Cancellation

Tissue RegenixAnnouncement

22/12/2025 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251222:nRSV5443Ma&default-theme=true

RNS Number : 5443M  Tissue Regenix Group PLC  22 December 2025

Tissue Regenix Group plc

('Tissue Regenix', the 'Group', or the 'Company')

 

Result of General Meeting

and

Cancellation

 

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company,
announces that at the General Meeting ('General Meeting') held earlier today,
all resolutions were duly passed on a show of hands.

 

The results of the proxy votes received in respect of the resolutions, given
to the Chair prior to the meeting, are set out below:

 

 Resolution            In favour   %     Against     %     Withheld
 1           Ordinary  18,821,081  65.4  9,979,283   34.6  20,362,691
 2           Ordinary  34,592,438  77.4  10,099,500  22.6  4,471,117
 3           Special   34,652,075  77.5  10,038,289  22.5  4,472,691
 4           Special   34,463,372  77.1  10,243,999  22.9  4,455,684
 5           Special   34,479,402  77.1  10,229,337  22.9  4,454,316
 6           Special   34,460,155  77.1  10,226,292  22.9  4,476,608

 

Notes:

1.     A "Vote withheld" is not counted in the calculation of the
percentage of shares voted "In favour" or "Against".

2.     As at 18 December 2025, being the voting deadline date in respect
of the General Meeting, the total number of Ordinary Shares of 0.1p each in
issue and the total number of voting rights was 71,395,635.

 

The full text of the resolutions passed at the General Meeting may be found in
the Notice of General Meeting section within the circular published and sent
to shareholders on 4 December 2025 ("the Circular").

 

The initial £7.5m of Secured Convertible Loan Notes from Harwood will
therefore now be issued by the Company.   Following the drawdown of the
£7.5m, the Company expects to be able to restore payments to creditors whilst
the new senior management look to stabilise the business and execute their
recovery plan to return the Company to profitability.

 

Cancellation

 

Further to the passing of Resolution 4, in accordance with Rule 41 of the AIM
Rules for Companies, the last day of admission of the Company's Ordinary
Shares to trading on AIM will be 6 January 2026, and cancellation of the
admission of the Company's Ordinary Shares to trading on AIM will become
effective on 7 January 2026. Following the Cancellation, the Company will
re-register as a private limited company and adopt new articles of
association, as detailed within the Circular.

 

The Company intends to provide a secondary market trading facility through
Asset Match, to enable Shareholders to trade in the shares on a periodic
basis. This facility will commence on 7 January 2026, following Cancellation
becoming effective. Further details on how to participate in the secondary
market trading facility via Asset Match are included within the Circular.

 

Commenting, Jay LeCoque, Executive Chairman, said: "I would like to thank all
of the shareholders who have voted in support of the resolutions, which was
essential for Tissue Regenix to continue as a viable business, and provides
the funding required to take full commercial advantage of our leading products
and superior technology. In particular, I would like to thank the team at
Harwood Private Equity, for providing significant financial security for the
business when no other options were available. Securing funding at this scale
and within such a tight frame was a remarkable achievement and I am very
grateful to everyone who has helped to make this happen.

 

"The business has excellent proprietary technology, a strong commercial
proposition, and a highly talented and dedicated group of employees, and so I
am delighted for the Tissue Regenix team, for our shareholders and for the
patients who will benefit from our technology, that our path forward is now
secured."

 

Defined terms not otherwise defined within this announcement have the same
meaning as given in the announcement published by the Company on 4 December
2025.

 

For more information, please contact:

 

 Tissue Regenix Group plc
 Jay LeCoque, Executive Chairman                                    via Walbrook PR

 Cavendish Capital Markets (Nominated Adviser and Broker)
 Geoff Nash/Edward Whiley/Hamza Munshi                              Tel: +44 (0) 20 7466 5000

 Nigel Birks - Life Science Specialist Sales

 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)  Tel: +44 (0)20 7933 8780 or TissueRegenix@walbrookpr.com

                                  (mailto:TissueRegenix@walbrookpr.com)
 Alice Woodings / Paul McManus

                                    Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

 

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold that is not rejected by the patient's body and can
be used to repair diseased or damaged body structures. Current applications
address many crucial clinical needs in sports medicine, foot and ankle
injuries, and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech
company specialises in regenerative medicine and is dedicated to developing
high-quality, innovative tissue scaffolds to enhance healing opportunities in
defects created by trauma and disease. CellRight's human tissue products may
be used in spine, trauma, general orthopaedic, dental and ophthalmological
surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMPKBBKABDDABB



            Copyright 2019 Regulatory News Service, all rights reserved